A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT

计划入组 25 人 · 首次发布于 2019 年 3 月 7 日

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)

计划入组 9 人 · 首次发布于 2019 年 3 月 14 日

A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma

计划入组 10 人 · 首次发布于 2024 年 12 月 4 日

ENKASTIM™

Covax-19™

Genenta Science

EMvision Medical Devices Ltd

Tempero Bio, Inc.

United States

Genenta Science's Temferon Receives Approval for Phase 1 Trial in Metastatic Renal Cell Carcinoma

Genenta Science Partners with Anemocyte to Advance Cell-Based Cancer Therapy Manufacturing

Genenta Science and Anemocyte Expand Partnership to Commercialize Lentiviral Vector Plasmid DNA Technology Platform